Breast Surgery — MCQs

Breast Surgery Indian Medical PG Practice Questions and MCQs

Question 171: Which is a distressing complication after modified radical mastectomy?

A. Lymphedema (Correct Answer)
B. Axillary vein thrombosis
C. Seroma
D. Death

Explanation: **Explanation:** **1. Why Lymphedema is the Correct Answer:** Lymphedema is considered the most **distressing and dreaded** long-term complication of Modified Radical Mastectomy (MRM). It occurs due to the disruption of lymphatic drainage following Axillary Lymph Node Dissection (ALND). The resulting chronic swelling of the arm leads to functional impairment, psychological distress, recurrent cellulitis, and, in rare cases, lymphangiosarcoma (Stewart-Treves Syndrome). While not immediately life-threatening, its chronic, progressive nature and impact on the quality of life make it the most "distressing" clinical outcome. **2. Analysis of Incorrect Options:** * **Axillary Vein Thrombosis:** This is a rare acute complication. While serious, it is far less common than lymphedema and usually manageable with anticoagulation. * **Seroma:** This is the **most common** early complication after MRM. While annoying and requiring frequent aspirations, it is usually self-limiting and does not cause the long-term morbidity associated with lymphedema. * **Death:** Mortality following MRM is extremely low (<0.1%) as it is a major but non-cavitary surgery. It is not a characteristic complication of the procedure itself. **Clinical Pearls for NEET-PG:** * **Most common complication:** Seroma formation. * **Most distressing/dreaded complication:** Lymphedema. * **Incidence of Lymphedema:** Approximately 10–30% after ALND; significantly reduced (<5%) with Sentinel Lymph Node Biopsy (SLNB). * **Nerve Injuries during MRM:** * **Long Thoracic Nerve (Bell’s):** Leads to Winging of Scapula. * **Thoracodorsal Nerve:** Leads to weakness in adduction/internal rotation (Latissimus dorsi). * **Intercostobrachial Nerve:** Most commonly injured nerve; leads to numbness of the inner aspect of the upper arm.

Question 172: Pain along the medial aspect of the arm in a post-mastectomy patient is due to:

A. Phantom breast pain
B. Intercostobrachial neuralgia (Correct Answer)
C. Neuroma pain
D. Other nerve injury pain

Explanation: **Explanation:** The correct answer is **Intercostobrachial neuralgia**. **1. Why it is correct:** The **intercostobrachial nerve** is the lateral cutaneous branch of the second intercostal nerve (T2). During axillary lymph node dissection (ALND) or a Modified Radical Mastectomy (MRM), this nerve is frequently encountered as it traverses the axilla to provide sensory innervation to the **skin of the axilla and the medial aspect of the upper arm**. Injury, traction, or division of this nerve leads to postoperative paresthesia, numbness, or chronic neuropathic pain (neuralgia) specifically localized to the medial arm. **2. Why the other options are incorrect:** * **Phantom breast pain:** This refers to the sensation of pain or discomfort in the breast tissue that has been surgically removed. It is a cortical phenomenon similar to phantom limb syndrome and is not localized to the arm. * **Neuroma pain:** While a neuroma (disorganized nerve regeneration) can cause localized trigger-point pain at the site of a surgical scar, it does not specifically target the medial arm distribution unless the intercostobrachial nerve itself is involved. * **Other nerve injury pain:** Injury to the Long Thoracic nerve (causing winged scapula) or the Thoracodorsal nerve (causing weakness in adduction/internal rotation) results in motor deficits rather than sensory pain in the medial arm. **3. High-Yield Clinical Pearls for NEET-PG:** * **Nerve Preservation:** Surgeons attempt to preserve the intercostobrachial nerve to prevent "Post-Mastectomy Pain Syndrome." * **Nerve of Bell:** Another name for the **Long Thoracic Nerve** (supplies Serratus Anterior). * **Nerve to Latissimus Dorsi:** Also known as the **Thoracodorsal Nerve**. * **Most common sensory deficit post-MRM:** Numbness in the medial arm due to intercostobrachial nerve injury.

Question 173: What is the LEAST diagnostic test for breast tumours?

A. Chest X-ray (Correct Answer)
B. Biopsy
C. USG
D. Mammography

Explanation: ### Explanation The diagnosis of a breast lump follows the **Triple Assessment** protocol, which includes clinical examination, imaging, and pathology. **Why Chest X-ray is the Correct Answer:** A Chest X-ray (CXR) is **not a diagnostic tool** for the primary breast tumor itself. It cannot differentiate between benign and malignant breast tissue, nor can it visualize the internal architecture of the breast. In the context of breast cancer, a CXR is used only as a **staging investigation** to look for distant pulmonary metastases or pleural effusion, rather than for diagnosing the primary lesion. **Why the other options are incorrect:** * **Mammography (D):** This is the gold standard screening and diagnostic imaging modality for women over 35–40 years. It identifies microcalcifications and architectural distortions. * **USG (C):** The investigation of choice for women under 30, pregnant women, and for differentiating between cystic and solid lesions. It also guides interventional procedures. * **Biopsy (B):** Specifically, **Core Needle Biopsy (CNB)** is the definitive diagnostic test. It provides histological details, including tumor grade and receptor status (ER/PR/HER2), which are essential for planning treatment. **Clinical Pearls for NEET-PG:** * **Triple Assessment:** Clinical Examination + Imaging (USG/Mammography) + Pathology (FNAC/Core Biopsy). It has a diagnostic accuracy of >99%. * **Gold Standard for Diagnosis:** Core Needle Biopsy (preferred over FNAC as it preserves tissue architecture). * **BIRADS Scoring:** Used in Mammography to communicate the risk of malignancy (BIRADS 1: Normal; BIRADS 5: Highly suggestive of malignancy). * **MRI Breast:** The most sensitive imaging for detecting breast cancer, especially in patients with BRCA mutations or breast implants.

Question 174: What is the best chemotherapy regimen for carcinoma of the breast?

A. Cyclophosphamide, adriamycin, 5-fluorouracil (Correct Answer)
B. Methotrexate, cisplatin
C. Cisplatin, adriamycin, steroid
D. Methotrexate, adriamycin, steroid

Explanation: **Explanation:** The treatment of breast cancer frequently utilizes polychemotherapy to improve survival rates. The combination of **Cyclophosphamide, Adriamycin (Doxorubicin), and 5-Fluorouracil (CAF)** is a classic, highly effective anthracycline-based regimen. 1. **Why Option A is correct:** * **Cyclophosphamide:** An alkylating agent that cross-links DNA. * **Adriamycin (Doxorubicin):** An anthracycline that inhibits topoisomerase II and generates free radicals. Anthracyclines are considered the "backbone" of breast cancer chemotherapy due to their superior efficacy in reducing recurrence. * **5-Fluorouracil:** An antimetabolite that inhibits thymidylate synthase. The CAF (or FAC) regimen has historically been the standard of care before the widespread introduction of taxanes (Paclitaxel/Docetaxel). 2. **Why other options are incorrect:** * **Option B & C:** Cisplatin is primarily used in triple-negative breast cancer (TNBC) or germline BRCA mutations, but it is not part of the standard first-line regimen for general breast carcinoma. * **Option D:** Methotrexate was part of the older CMF regimen (Cyclophosphamide, Methotrexate, 5-FU), but it is generally less effective than anthracycline-based regimens like CAF. Steroids are supportive (anti-emetics) but not primary chemotherapeutic agents. **High-Yield Clinical Pearls for NEET-PG:** * **Cardiotoxicity:** Adriamycin is notorious for dose-dependent irreversible dilated cardiomyopathy. Monitor with ECHO (LVEF). * **Hemorrhagic Cystitis:** Associated with Cyclophosphamide; prevented by hydration and **MESNA**. * **Taxanes:** Modern regimens often add Taxanes (e.g., AC → T) for node-positive or high-risk disease. * **Trastuzumab (Herceptin):** Specifically used for **HER2/neu positive** patients; note that it also carries a risk of reversible cardiotoxicity.

Question 175: Which is the most common benign breast condition that presents in young females as a palpable lump?

A. Fibroadenoma (Correct Answer)
B. Phyllodes tumor
C. Ductal carcinoma in situ (DCIS)
D. Lobular carcinoma in situ (LCIS)

Explanation: **Explanation:** **Fibroadenoma** is the most common benign breast tumor in young women, typically occurring between the ages of 15 and 35. It is a fibroepithelial tumor characterized by the proliferation of both glandular and stromal elements. Clinically, it presents as a firm, painless, highly mobile, and well-circumscribed mass, earning it the classic moniker **"Breast Mouse"** because it slips away from the examining fingers. Its development is estrogen-dependent, often enlarging during pregnancy and involuting after menopause. **Analysis of Incorrect Options:** * **Phyllodes Tumor:** While also a fibroepithelial lesion, it is much rarer than fibroadenoma and typically presents in an older age group (40–50 years). It is characterized by rapid growth and a leaf-like (phyllodes) appearance on histology. * **DCIS and LCIS:** These are "in situ" carcinomas. They are not benign conditions; they are pre-malignant or marker lesions for malignancy. Furthermore, they rarely present as a palpable lump in young females; DCIS is most commonly detected as microcalcifications on screening mammography in older women. **High-Yield Clinical Pearls for NEET-PG:** * **Triple Assessment:** The gold standard for diagnosis includes Clinical Examination, Imaging (Ultrasound is preferred in women <30 years), and Pathology (FNAC or Core Needle Biopsy). * **Mammography Finding:** May show "Popcorn calcification" in older, involuting fibroadenomas. * **Management:** Conservative management is appropriate for small, asymptomatic lesions. Surgical excision is indicated if the lump is >3 cm, rapidly increasing in size, or if the patient requests removal.

Question 176: What is the commonest carcinoma of the breast with multifocal origin?

A. Schirrhous carcinoma
B. Adenocystic carcinoma
C. Lobular carcinoma
D. Ductal carcinoma (Correct Answer)

Explanation: ### Explanation The correct answer is **Ductal Carcinoma**. **1. Why Ductal Carcinoma is Correct:** In modern breast surgery literature and clinical practice, **Infiltrating Ductal Carcinoma (IDC)**—specifically the "No Special Type" (NST)—is the most common histological subtype of breast cancer. While Lobular Carcinoma is famously associated with multicentricity, **Ductal Carcinoma is the commonest subtype to present with multifocal origin** simply because it is the most prevalent form of breast cancer overall (accounting for 70–80% of cases). *Note on Terminology:* **Multifocal** refers to multiple foci of tumor within the same quadrant, whereas **Multicentric** refers to tumors in different quadrants. Ductal carcinoma frequently presents with multiple satellite nodules or extensive DCIS components, making it the most frequent cause of multifocality in absolute numbers. **2. Why the Other Options are Incorrect:** * **Lobular Carcinoma (C):** While Invasive Lobular Carcinoma (ILC) has a *higher percentage* of multicentricity and bilaterality compared to IDC, it is significantly less common overall. If the question asks for the "commonest" (absolute frequency), Ductal Carcinoma is the answer. * **Schirrhous Carcinoma (A):** This is an older descriptive term for a variant of ductal carcinoma characterized by dense fibrous stroma (desmoplasia). It is not a distinct origin-based category. * **Adenocystic Carcinoma (B):** This is a rare variant of breast cancer (more common in salivary glands) with a generally favorable prognosis; it is rarely multifocal. **3. Clinical Pearls for NEET-PG:** * **Most common breast cancer:** Infiltrating Ductal Carcinoma (NST). * **Highest risk of bilaterality/multicentricity:** Invasive Lobular Carcinoma (ILC). * **E-cadherin loss:** The hallmark molecular marker for Lobular Carcinoma (helps differentiate it from Ductal). * **Paget’s Disease of the nipple:** Usually associated with an underlying Ductal Carcinoma (DCIS or Invasive). * **Most common site:** Upper Outer Quadrant (UOQ).

Question 177: A patient presents 1 month after a benign right breast biopsy with a lateral subcutaneous cord felt just under the skin and causing pain. What is the etiology of this condition?

A. Fat necrosis
B. Infection
C. Superficial thrombophlebitis (Correct Answer)
D. Suture granuloma

Explanation: **Explanation:** The clinical presentation of a palpable, tender, subcutaneous "cord-like" structure following breast surgery or trauma is classic for **Mondor’s Disease**, which is **superficial thrombophlebitis** of the veins of the breast and anterior chest wall. It most commonly involves the lateral thoracic vein, superior epigastric vein, or thoracoepigastric vein. **Why the correct answer is right:** * **Superficial Thrombophlebitis (Mondor’s Disease):** This is a benign, self-limiting condition. The "cord" represents a thrombosed vein. It typically presents 2–6 weeks after surgery (like biopsy or augmentation), trauma, or even extreme physical activity. The pain is usually acute but subsides as the cord becomes more fibrous. **Why the incorrect options are wrong:** * **Fat Necrosis:** Usually presents as a firm, irregular, painless mass following trauma. While it can mimic carcinoma clinically, it does not present as a longitudinal subcutaneous cord. * **Infection:** Post-operative infections (abscess or mastitis) present with systemic symptoms (fever), localized warmth, erythema, and fluctuance, rather than a distinct, non-erythematous cord. * **Suture Granuloma:** This is a localized inflammatory response to suture material, presenting as a small, firm nodule at the site of the incision, not a linear cord extending across the breast. **NEET-PG High-Yield Pearls:** * **Management:** Mondor’s disease is **self-limiting**. Treatment is conservative with NSAIDs and warm compresses. Anticoagulants are NOT indicated. * **Physical Sign:** The "Iron Wire" sign—the cord may become more prominent when the patient raises their arm. * **Association:** While usually benign/traumatic, in rare cases, it can be a marker for underlying breast malignancy; hence, a follow-up mammogram is often advised if not recently performed.

Question 178: Pathological nipple discharge is most commonly associated with which of the following?

A. Fibroadenoma
B. Duct papilloma (Correct Answer)
C. Adenocarcinoma
D. Lobular carcinoma

Explanation: **Explanation:** Nipple discharge is classified as **pathological** if it is spontaneous, unilateral, and arises from a single duct. The most common cause of such discharge (especially if bloody or serosanguinous) is an **Intraductal Papilloma**. 1. **Why Duct Papilloma is Correct:** Intraductal papillomas are benign, finger-like epithelial proliferations within the lactiferous ducts. Because these growths are fragile and highly vascular, they tend to bleed easily into the ductal lumen, leading to the classic presentation of a **spontaneous, bloody nipple discharge** in women aged 30–50. It is typically non-palpable and located in the subareolar region. 2. **Why the Other Options are Incorrect:** * **Fibroadenoma:** This is the most common benign breast tumor ("breast mouse"), but it arises from the terminal duct lobular unit (TDLU) and presents as a firm, mobile mass, not with nipple discharge. * **Adenocarcinoma (Invasive Ductal Carcinoma):** While malignancy is the second most common cause of pathological discharge (approx. 5-15% of cases), it is less frequent than papilloma. Malignant discharge is more likely to be associated with a palpable mass or skin changes. * **Lobular Carcinoma:** This often presents as an occult, multifocal, or bilateral thickening rather than a discrete mass or nipple discharge. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of bloody nipple discharge:** Intraductal Papilloma. * **Most common cause of milky discharge (Galactorrhea):** Prolactinoma (Pituitary adenoma). * **Investigation of choice:** Triple assessment (Clinical exam + Imaging + Cytology/Biopsy). For single-duct discharge, **Microdochectomy** (removal of the involved duct) is both diagnostic and therapeutic. * **Amniotic fluid-like/Greenish discharge:** Usually associated with **Mammary Duct Ectasia**.

Question 179: A 17-year-old male develops a painless, firm mass beneath the nipple of his left breast. The mass is mobile, and no fluid can be expressed from the breast. The right breast is normal to examination. Which of the following conditions does this mass most likely represent?

A. Fibrocystic changes
B. Gynecomastia (Correct Answer)
C. Intraductal papilloma
D. Invasive duct carcinoma

Explanation: ### **Explanation** The clinical presentation of a firm, mobile, subareolar mass in an adolescent male is classic for **Gynecomastia**. **1. Why Gynecomastia is Correct:** Gynecomastia is the benign proliferation of glandular breast tissue in males. It typically presents as a **rubbery or firm, mobile, disc-like mass** located concentrically beneath the nipple-areolar complex. In adolescents (pubertal gynecomastia), it is extremely common (up to 60% of boys) due to a transient imbalance between estrogen and androgen action. It is often unilateral or asymmetrical and usually resolves spontaneously within 1–2 years. **2. Why the Other Options are Incorrect:** * **Fibrocystic changes:** These are common in females due to cyclical hormonal fluctuations but are virtually non-existent in the male breast, which lacks developed acini and lobules. * **Intraductal papilloma:** This typically presents with **serous or bloody nipple discharge**. While it causes a subareolar mass, it is rare in males and does not fit the age profile as well as gynecomastia. * **Invasive duct carcinoma:** Although it can occur in males, it is exceptionally rare at age 17 (median age is >60). Malignancy usually presents as a hard, fixed, eccentric mass, often with skin changes or lymphadenopathy. ### **High-Yield Clinical Pearls for NEET-PG:** * **Trimodal Distribution:** Gynecomastia peaks during the neonatal period, puberty, and old age (senescence). * **Drug-Induced Gynecomastia (Mnemonic: DISCO):** **D**igoxin, **I**soniazid, **S**pironolactone, **C**imetidine, **O**estrogens/Ketoconazole. * **Pathology:** Unlike the female breast, gynecomastia is characterized by **ductal hyperplasia** and stroma expansion; **true lobule formation is absent** unless the patient has been exposed to high levels of exogenous progesterone. * **Management:** Reassurance is the first step for pubertal gynecomastia. Persistent cases may require medical (Tamoxifen) or surgical (subcutaneous mastectomy) intervention.

Question 180: Which of the following is NOT a risk factor for breast carcinoma?

A. Oral contraceptive pills (OCP) (Correct Answer)
B. Early menarche
C. Family history
D. Late menopause

Explanation: **Explanation:** The risk of breast carcinoma is primarily linked to the **cumulative lifetime exposure to estrogen**. Factors that increase the number of menstrual cycles or provide exogenous hormonal stimulation generally elevate this risk. **Why OCP is the correct answer:** While long-term use of Oral Contraceptive Pills (OCPs) was historically debated, modern large-scale studies and meta-analyses (such as those by the Collaborative Group on Hormonal Factors in Breast Cancer) show that the **relative risk associated with OCPs is negligible or non-significant** for the general population. In the context of NEET-PG, OCPs are generally considered to have a protective effect against ovarian and endometrial cancers, while their link to breast cancer is considered weak or absent compared to the definitive risk factors listed in the other options. **Analysis of Incorrect Options:** * **Early Menarche (<12 years):** Increases the total number of ovulatory cycles and lifetime estrogen exposure, thereby increasing risk. * **Late Menopause (>55 years):** Similarly extends the duration of estrogen exposure, doubling the risk compared to women who undergo menopause before age 45. * **Family History:** A first-degree relative with breast cancer significantly increases risk (2-fold if one relative, 3-fold if two), especially if associated with BRCA1/BRCA2 mutations. **High-Yield Clinical Pearls for NEET-PG:** * **Protective Factors:** Early pregnancy (<20 years), breastfeeding, and physical activity. * **Modifiable Risk Factors:** Obesity (post-menopausal), alcohol consumption, and Hormone Replacement Therapy (HRT)—unlike OCPs, HRT is a significant risk factor. * **Nulliparity:** Increases risk, whereas multiparity is protective.

Practice by Chapter

Breast Anatomy and Physiology

Practice Questions

Benign Breast Diseases

Practice Questions

Breast Cancer Screening

Practice Questions

Breast Cancer: Diagnosis and Staging

Practice Questions

Surgical Management of Breast Cancer

Practice Questions

Oncoplastic Breast Surgery

Practice Questions

Sentinel Lymph Node Biopsy

Practice Questions

Axillary Surgery

Practice Questions

Breast Reconstruction Techniques

Practice Questions

Male Breast Disorders

Practice Questions

Phyllodes Tumors

Practice Questions

Management of Ductal Carcinoma In Situ

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free